↓ Skip to main content

Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis

Overview of attention for article published in Diabetes Therapy, August 2018
Altmetric Badge

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
64 Mendeley
Title
Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis
Published in
Diabetes Therapy, August 2018
DOI 10.1007/s13300-018-0482-5
Pubmed ID
Authors

Dan Qian, Tiantian Zhang, Peiying Zheng, Zhuoru Liang, Sen Wang, Jingmei Xie, Lina Zhao, Ying Zhang, Bing Situ

Abstract

We assessed the efficacy and safety of oral antidiabetic drugs (OADs) as an add-on treatment in patients with type 2 diabetes uncontrolled on metformin. PubMed, the Cochrane Library, and Embase were searched from inception to October 20, 2017. Pairwise and network meta-analyses were conducted using Stata 14.1 software. Odds ratios (ORs) and weighted mean differences (WMDs) were used to evaluate outcomes. Sixty-eight trials including 36,746 patients were analyzed. No significant differences in the risk of major adverse cardiovascular events (MACEs) and all-cause mortality were observed among any class of OADs when combined with metformin. All classes of OADs as add-ons to metformin improved glucose control, while sodium-glucose co-transporter-2 (SGLT-2) inhibitors showed greater fasting plasma glucose (FPG) reductions {WMD, - 1.49 [95% confidence interval (CI) - 1.69 to - 1.28] mmol/l} and 2 h postprandial glucose (2 h PPG) reductions [WMD, - 3.07 (95% CI - 4.12 to - 2.03) mmol/l]. Thiazolidinediones and sulfonylureas were associated with weight gain [WMD, 2.53 (95% CI 1.95-3.10) kg and 2.00 (95% CI 1.63-2.36) kg, respectively] when added to metformin. Sulfonylureas [WMD, 6.52 (95% CI 4.07-10.45)] were associated with the highest ORs of hypoglycemia. Our results suggest that the seven classes of OADs were not associated with any increased risk of MACEs or all-cause mortality when combined with metformin. Most OADs were associated with similarly large reductions in HbA1c levels when added to metformin, while SGLT-2 inhibitors might be the best option for reducing body weight, FPG, and 2-h PPG.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 64 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 16%
Student > Master 8 13%
Researcher 7 11%
Student > Postgraduate 4 6%
Student > Ph. D. Student 3 5%
Other 4 6%
Unknown 28 44%
Readers by discipline Count As %
Medicine and Dentistry 17 27%
Pharmacology, Toxicology and Pharmaceutical Science 8 13%
Arts and Humanities 2 3%
Biochemistry, Genetics and Molecular Biology 2 3%
Nursing and Health Professions 2 3%
Other 5 8%
Unknown 28 44%